Interestingly, Vadadustat, an α-ketoglutarate analog that acts as a PDH inhibitor and thus is capable of stabilizing HIF-1α, is currently in clinical trials to treat acute respiratory distress syndrome (ARDS) in COVID-19 patients (https://clinicaltrials.gov/ct2/show/NCT04478071 (accessed on 4 July 2021)). The gene discussed is HIF1A; the disease is acute respiratory distress syndrome.